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Abstract
Background: One medication commonly used by HIV-1-infected individuals is the antimicrobial sulphamethoxazole
(SMX), which is used in the treatment and prophylaxis of pneumocystis pneumonia. However, SMX is responsible
for a very high incidence of hypersensitivity adverse drug reactions (ADRs) in the HIV-1 population. While the
pathophysiology of ADRs in general is unknown, sulphamethoxazole-mediated ADRs have been linked to its reactive
metabolite sulphamethoxazole-hydroxylamine (SMX-HA). Our previous work has shown that increased expression
of the HIV-1 Tat protein in T cells correlated with increased apoptosis after incubation with SMX-HA. In this study we
sought to determine the region of the Tat protein responsible for this effect and the mechanism by which Tat contributed
to SMX-HA mediated apoptosis.
Methods: We established Jurkat T and Cos 7 cell lines that stably expressed full-length Tat (Tat101) and deletion
mutants (Tat86, Tat72, Tat48 and Tat∆). These cell lines were then incubated with SMX-HA and assayed for cell viability
and production of reactive oxygen species (ROS). We further used confocal microscopy to assess the intracellular
distribution of the Tat proteins and to determine if changes in the expression and/or localization of key cytoskeleton
proteins contributed to Tat-mediated apoptosis after SMX-HA treatment.
Results: Deletion of regions of Tat that lead to increased cytoplasmic accumulation significantly contributed to
increased cell death in the presence of SMX-HA. The increased cell death did not require induction of ROS. Quantitative
analysis also showed that the Tat-expressing cell lines had significantly lower levels of β-actin and α-tubulin present
both before and after treatment with SMX-HA. Increased cytoplasmic localization of Tat correlated with greater
disturbances in the distribution of actin filaments.
Conclusion: The presence of cytoplasmic Tat in T and epithelial cell lines increases their sensitivity to SMX-HA
induced cell death, an effect mediated by the first 48 amino acids of TAT.

Keywords: HIV-1 Tat; Jurkat T cell; Cos 7; Sulphamethoxazole;
Sulphamethoxazole-hydroxylamine; Hypersensitivity adverse drug
reactions
List of Abbreviations: ADRs: Adverse Drug Reactions;
AIDS: Acquired Immuno Deficiency Syndrome; HIV-1: Human
Immunodeficiency Virus type 1; LTR: Long Terminal Repeat; NLS:
Nuclear Localization Sequence; PCAF: P300/CREB-binding protein
Associated Factor; PTD: Protein Transduction Domain; P-TEFb:
Positive Transcriptional Elongation Factor b; ROS: Reactive Oxygen
Species; SMX: Sulphamethoxazole; SMX-HA: SulphamethoxazoleHydroxylamine; SMX-TMP: Sulphamethoxazole-Trimethoprim; TAR:
Tat Activation Region; Tat: Transactivator of transcription
Introduction
An important consequence of human immunodeficiency virus type
1 (HIV-1) infection is the decline of the individual’s immune system,
which allows for vulnerability to opportunistic diseases. The fungus
Pneumocystis jirovecii takes advantage of this immunodeficiency to
elicit Pneumocystis pneumonia, a lung infection that is commonly
treated with the antimicrobial sulphamethoxazole-trimethoprim
(SMX-TMP), more commonly known as cotrimoxazole. This standard
combination of two antimicrobials is also used to treat urinary tract
infections in the HIV-1-negative population. The SMX moiety of the
drug has been associated with risk of adverse drug reactions (ADRs)
at an incidence of 2-5% [1]. However, the incidence of SMX ADRs
increases to 50% or more in HIV-1 infected individuals as progression
to AIDS occurs [1]. ADRs are conventionally defined as a response to
a drug that is noxious and unintended, occurring at doses normally
used for prophylaxis or treatment [2]. One of the most serious types
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of ADRs are the hypersensitivity ADRs which usually present as a
delayed reaction characterized by the onset of fever and a rash that can
often develop into serious skin conditions such as Stevens-Johnson
syndrome or toxic epidermal necrolysis, both of which can be fatal [2].
Clinical manifestations of hypersensitivity ADRs are highly diverse
and often involve numerous organs such as the liver and kidneys
[2]. These symptoms are similar in HIV-1-infected and uninfected
patients, however severe reactions such as Stevens-Johnson syndrome
or toxic epidermal necrolysis are much more common in HIV-1infected individuals [3]. The risk of an SMX-induced ADR significantly
increases as HIV-1 infection progresses to AIDS, specifically when
HIV-1 infection is uncontrolled which suggests that virus infection
can adversely modify the manner in which host-drug interactions take
place.
The hapten hypothesis has been advanced as being key to the
pathogenesis of drug hypersensitivity in general and those stimulated
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by SMX in particular. This hypothesis postulates that bioactivation and
haptenation of the drug to a cellular protein or proteins is critical to
the initiation of an immune response. Sulphamethoxazole undergoes
bioactivation by the cytochrome P450 enzyme CYP2C9 to its
hydroxylamine metabolite that is then auto-oxidized to nitroso-SMX,
both of which are known to be toxic to cells in vitro [4,5]. Indeed, this
toxicity was the basis for an in vitro model of hypersensitivity ADRs
as peripheral blood lymphocytes from patients with a history of
hypersensitivity ADRs showed significantly increased toxicity across a
concentration range of SMX-HA compared to those from controls and
patients with a history of non-hypersensitivity reactions [6]. A similar
finding was reported in HIV-1-positive patients where SMX-HA
cytotoxicity was greater in patients known to exhibit hypersensitivity
ADRs [7] and, as we previously demonstrated, also correlated with
HIV-1 infection in established T cell lines and with the expression of
recombinant HIV-1 Tat (Transactivator of transcription) protein in T
cell lines [4,8].
Tat is a small, non-structural transcriptional regulator essential for
the efficient replication of HIV-1. Tat binds to the TAR (Tat activation
region) sequence, a stable RNA hairpin that forms at the end of all
nascent viral transcripts, which leads to the recruitment and activation
of cellular factors that potentiate RNA polymerase II to synthesize fulllength HIV-1 transcripts [9]. The coding sequences of the Tat gene are
located on two exons and the resultant protein has a molecular weight
of 14-16 kDa. Tat is made up of 101 amino acids with residues 1-72
encoded by the first exon and residues 73-101 encoded by the second
exon. The 101 amino acid form of Tat is what is found predominantly
in clinical isolates from all HIV-1 subtypes except subtype D, which
has a non-synonymous single nucleotide polymorphism creating a stop
codon in the second exon and an 86 amino acid protein [10]. Though
a few laboratory strains exist that express an 86 amino acid form of
Tat, this version is thought to represent an artificially truncated protein
[11,12].
The full-length Tat protein can be divided into six domains: the
N-terminal domain (aa 1-21), cysteine-rich domain (aa 22-37), core
domain (aa 38-47), basic domain (aa 48-60), glutamine-rich domain
(aa 61-72) and the C-terminal domain (aa 73-101) [10,13]. The first
three domains (aa 1-48) together contain the minimum activation
domain of the protein which mediates its interactions with cellular
transcription machinery [9,14,15]. The basic domain in conjunction
with the glutamine-rich domain confers the Tat activation region (TAR)
RNA binding properties to Tat. Therefore the product of the first exon
(aa 1-72), representing the activation domains and the TAR-binding
region, is all that is required for functional HIV-1 transactivating
activity. The basic domain is also known as the protein transduction
domain (PTD) and contains a nuclear localization sequence (NLS). The
PTD confers on Tat the ability to exit HIV-1 infected cells and enter
uninfected bystander cells. This form of Tat is known as extracellular Tat
and is able to modulate gene expression of a number of cellular genes
in both infected and uninfected cells [9,16]. Ultimately, extracellular
Tat is thought to facilitate the spread and pathogenesis of HIV-1 by
contributing to the apoptosis and eventual depletion of the CD4+ T cell
subset [17-20].
We have previously demonstrated SMX-HA induced cell death via
apoptosis in a cultured T cell line expressing the first exon of the HIV1 Tat protein [21]. Here we determine the mechanism by which SMX
-HA enhances Tat’s ability to promote apoptosis using the full-length
form of Tat. One mechanism by which Tat has been demonstrated to
enhance apoptosis is by the production of reactive oxygen species (ROS)
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[12], therefore we looked at ROS production in the Tat-expressing cell
lines in the absence and presence of SMX-HA. Another pro-apoptotic
mechanism utilized by extracellular Tat involves its specific interaction
with the αβ-tubulin dimer and polymerized microtubules of the
cytoskeleton [22]. This Tat-tubulin interaction is dependent on residues
36-39 which is a four-amino-acid subdomain that overlaps with the
core domain [22]. Tat has also been shown to affect the rearrangement
of the actin cytoskeleton [23]. In the current study we determined
which region of the Tat protein facilitated the cellular toxicity to SMXHA and if there was any correlation to the expression of cytoskeletal
proteins. We also determined if changes in the expression and/or
localization of key cytoskeleton proteins enhances apoptosis of Jurkat
T cells expressing intracellular Tat, when the protein is synthesized
inside the cell as during an HIV-1 infection. We provide new evidence
that in the presence of both HIV-1 Tat and SMX-HA, a T cell is more
susceptible to apoptotic cell death and may be the first step in a cascade
of events that leads to the increase in SMX-associated ADR in HIV-1
infected persons.

Materials and Methods
Cell lines
The human T lymphocyte cell line Jurkat E6.1 (ATCC TIB-152),
was obtained from the American Type Culture Collection (ATCC). The
cell line was maintained in Complete RPMI 1640 medium (Invitrogen)
supplemented with 1% L-glutamine, 10% fetal calf serum and 100
units/ml of penicillin and streptomycin. The Cos-7 cell line (ATCC
CRL 1651), a monkey kidney fibroblast-like cell line was maintained
in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal
calf serum and 100 units/ml of penicillin and streptomycin.
Construction of plasmids and cell lines: The Tat gene was PCRamplified from the plasmid pSVTat. This plasmid encodes the fulllength Tat gene and was a kind gift from Dr. KT Jeang at the Laboratory
of Molecular Microbiology, the Molecular Virology Section, NIAID,
NIH. The full-length Tat gene (Tat101), with or without stop codons,
and Tat deletion mutants (Tat86, Tat72, Tat48 and Tat∆(49-59)) were
cloned into the plasmid pEGFP-N1 (Clontech Inc.), resulting in
Tat101, Tat101GFP, Tat86GFP, Tat72GFP, Tat48GFP and Tat∆GFP
fusion gene, respectively. The fusion genes were then subcloned into
pBIG2i as previously described [21]. The results were the following
plasmid constructs; pBIG Tat101, pBIG Tat101GFP, pBIG Tat86GFP,
pBIG Tat72GFP, pBIG Tat48GFP and pBIG Tat∆GFP. As a control, the
GFP gene from pEGFP-N1 was also cloned into pBIG2i to create pBIG
GFP. The pBIG Tat constructs or pBIG GFP were transfected into Jurkat
E6.1 T cells by nucleofection (Lonza, Amaxa Nucleofector) according
to the manufacturer’s instructions and stable cell lines were generated
as previously described [21]. Cos-7 cells were also transfected with
the pBIG TatGFP constructs for confocal microscopy studies. The
expression of the fusion proteins or GFP in either cell type was induced
by incubating the transfected cells with doxycycline (Sigma, Canada).

Source of SMX-HA
SMX-HA was synthesized by Katarina Sapeta in the laboratory of
Dr. Michael A. Kerr at the Department of Chemistry, the University of
Western Ontario.
Dose response and time course of doxycycline induction: The
concentration of doxycycline required to induce expression of the
TatGFP fusion proteins was determined in dose-response experiments
where cells from the different cell lines were incubated with 0-1000
ng/ml of doxycycline for 40 h and then the cells were analyzed on a
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FACS (fluorescence-activated cell sorting) Calibur instrument (Becton
Dickinson). Time course experiments were conducted by incubating
cells with 0-1000 ng/ml of doxycycline for 72 h, with aliquots taken
at 12 h intervals and analyzed by flow cytometry on a FACS Calibur.
In both the dose response and time course experiments at least
10,000-gated events were measured for each sample. Flow cytometry
data were analyzed and the percentage of GFP+ cells determined using
the FlowJo program (Tree Star, Inc.).

Real time PCR analyses of Tat/GAPDH mRNA levels
To compare the level of Tat mRNA present in the stable cell lines
with that in HIV-1-infected cells, cells from each of the stable pBIG
TatGFP cell lines were induced by treatment with 0, 200, 400, 600, 800
and 1000 ng/ml doxycycline for 40h and total RNA was extracted using
the RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions.
RNA was also isolated from HIV-1IIIB-infected Jurkat T cells. Total
RNA (10 μg) was reverse transcribed using the High Capacity cDNA
Archive Kit (Applied Biosystems) according to the manufacturer’s
instructions. Control real time-PCR reactions were performed in
the absence of cDNA templates and GAPDH was used as a control
housekeeping gene. Real time-PCR analysis was performed using the
ABI PRISM 7900HT Sequence Detection System (Applied Biosystems)
with TaqMan assays. Relative expression levels were determined by the
comparative cycle threshold method [24].

Western blot analysis
To characterize the expression of the TatGFP fusion proteins in the
Jurkat T cell lines, cells were differentially induced with doxycycline for
40 h, washed twice in PBS then solubilized with RIPA buffer containing
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton x-100, 1% Sodium
deoxycholate, 0.1% SDS, 1 mM EDTA and complete mini protease
inhibitor cocktail (Roche). The lysates were sonicated for 2 × 20 sec
then centrifuged at 13,000 rpm for 15 min at 4°C. The supernatants
were collected and the protein concentrations were determined using
the DC Protein Assay (BioRad) and bovine serum albumin (BSA)
as standards. The proteins were resolved on a 15% SDS-PAGE gel,
transferred to a PVDF (polyvinylidene difluoride) membrane and
probed for Tat (Advanced Biotechnologies Inc.). Bound antibody was
detected using goat anti-mouse horseradish peroxidase-conjugated
secondary antibody and enhanced chemiluminescence (Amersham).
GAPDH (Sigma) was used as a control for protein loading.
Tat-expressing Cos-7 cells were seeded in 6-well plates at a density
of 2 x 105 cells/well and induced with 0, 200 or 2000 ng/ml doxycycline
for 40 h. The cells were washed with PBS and treated with 0.05%
DMSO (vehicle) or 200 µM SMX-HA diluted in HEPES buffer for 2h
at 37°C. This was followed by another 2 h incubation with media at
37°C after which the cells were collected and protein extracted as stated
above. 1 µg of BSA was added to each 20 µg sample of protein that
was then resolved on 12% SDS-PAGE. The proteins were transferred
onto PVDF membranes and probed with anti-α-tubulin (Sigma
Aldrich), anti-β-actin (Sigma Aldrich) or anti-BSA (Life Technologies)
antibodies. Densitometric analysis was performed with FlouChem Q
(AlphaInnotech) using BSA as a loading control.

MTT cell viability assay
Drug toxicity was measured using the MTT (3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; SigmaAldrich) cell proliferation assay. Cell proliferation was quantified by
colorimetric conversion of MTT [25]. Briefly, Jurkat pBIG TatGFP
cells were differentially induced with doxycycline for 40 h, washed
HIV Curr Res
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twice with PBS then 7.5 x 104 cells/well were seeded in 96-well plates
and incubated in HEPES buffer with 200 µM SMX (Sigma-Aldrich) or
0-400 µM of SMX-HA for 2 h. After the drug was removed, the cells
were resuspended in media and incubated at 37°C for 18 h. Next, 1
mg/ml MTT was added to the wells and incubated at 37°C for another
4 h. The reaction product that precipitated was solubilized overnight
at room temperature by the addition of the stop solution (50% N,
N-dimethylformamide/ 20% SDS) to the wells. The following morning
the absorbance in the wells was determined by an ELISA plate reader at
590 nm and equated to the percentage of viable cells with the help of a
standard curve. This assay was performed on three separate occasions
for each cell line.

Detection of reactive oxygen species
Following the 40 h doxycycline induction, the cells were washed
twice in PBS and resuspended in HBSS (Hank’s buffered saline solution)
at a concentration of 1 × 106 cells/ml. Cell suspension (100 µl) was placed
in wells of a 96-well plate, the plate centrifuged at 1500 rpm for 5 min
and the supernatant decanted. To each well 100 µl of 20 µM DCFH-DA
(2’, 7’-dichlorfluorescein-diacetate, Sigma) in HBSS was added and the
plate was incubated at 37°C for 1h after which the plate was centrifuged
at 1500 rpm for 5 min and the supernatant decanted. The wells were
filled with 100 µl HBSS and background fluorescence read at 485 nm
excitation and 527 nm emission. SMX-HA was added to the wells in
quadruplicates and the plate is incubated at 37°C with fluorescence
readings at 30 min intervals for 2 h. This assay was performed on three
separate occasions for each cell line.

Confocal microscopy
Mitochondrial imaging - Cos 7 pBIG TatGFP cells were incubated
with 500 ng/ml of doxycycline for 40h, incubated with 6 µM MitoTracker
Far Red (Invitrogen) and 10 µM Hoechst 33258 (Sigma-Aldrich) for 20
min at 37°C.
Cytoskeletal imaging - Cos 7 cells were incubated with 500 ng/
ml of doxycycline for 40 h, treated with 200 µM SMX-HA for 2 h at
37°C and then incubated with media only for an additional 2 h, again
at 37°C. The cells were stained with 10 µM Hoechst 33258 for 15 min
at 37°C, then washed with PBS, fixed with 1% paraformaldehyde (PFA)
for 10 min at room temperature and permeabilized with cold acetone
at -20°C for 4 min. The rest of the procedure was carried out at room
temperature. Cells were washed thrice with PBS, blocked with 1% BSA
for 30 min and then incubated with mouse monoclonal anti-α-tubulin
(Sigma Aldrich) for 30 min. After three more washes with PBS the cells
were incubated with Alexa Flour 633 goat anti-mouse IgG (Molecular
Probes) for 30 min and then Alexa Flour 546 phalloidin (Molecular
Probes) was added for 20 min.
The images were taken with a Zeiss LSM 510 META confocal
microscope and processed using Image-Pro 5.0 (Media Cybernetics)
and Adobe Photoshop CS2 (Adobe Systems, Inc.). The actin proteins
were pseudocoloured.

Statistics
MTT cell viability data were analyzed in GraphPad Prism version
5 (GraphPad Software Inc., San Diego, CA). A two-way ANOVA with
Bonferonni’s post hoc procedure was used to compare mean differences
between groups for different concentration levels. The LC50 values were
calculated using GraphPad Prism 5, where the X values (concentration
of SMX-HA) were log-transformed and the Y values (% cell viability)
were normalized to define 0% and 100% as the smallest and highest
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values, respectively. This was followed by sigmoidal dose-response
(variable slope) curve-fit. GraphPad Prism (GraphPad Software Inc.,
San Diego, CA) was also used to calculate mean and standard error for
the real time-PCR data as well as the western blot densitometer data.

Results
TatGFP constructs
As we have previously established that T cells undergo apoptosis
when expressing HIV-1 Tat and exposed to SMX-HA (8, 21), we wanted
to understand the mechanism(s) behind the increased sensitivity
to SMX-HA including what regions or properties of Tat contributed
to this process. We began by constructing and expressing full length
Tat and Tat deletion mutants (Figure 1) fused to EGFP as previously
described [21]. Briefly, the full-length HIV-1 Tat protein (Tat101)
was PCR amplified and subcloned onto the N-terminal end of an
EGFP plasmid to create the fusion protein Tat101GFP. Five deletion
mutants of the Tat protein were similarly generated to produce the TatEGFP fusion protein constructs Tat48GFP, Tat72GFP, Tat86GFP and
Tat∆GFP, which expressed the full-length protein without the NLS/
PTD. The fusion constructs were inserted into a doxycycline-inducible
vector pBIG2i and subsequently used to establish stably transfected
Jurkat E6.1 T and Cos-7 cell lines derived from single cell clones.

Characterization of the TatGFP-expressing cell lines
Each stably transfected Jurkat T cell line was characterized by
western blotting to determine if the Tat portion of the correct fusion
proteins was present. To this end, cells from each of the lines were
incubated for 40 h with 0-1000 ng/ml Dox then lysed and protein
extracted. The use of specific anti-Tat antibodies showed the induction
of the TatGFP fusion protein of the correct size in each of the cell lines
at different concentrations of doxycycline (Figure 1). An analogous
experiment was carried out with stably transfected Cos7 cells that
were incubated with 0-2000ng/ml Dox before protein extraction. The
increasing expression of the TatGFP proteins was observed in these cell
lines, similar to that seen in the Jurkat cell lines (data not shown).
Time course experiments were carried out to determine the
induction profile of each Tat fusion protein expression at different
doxycycline concentrations as well as the point at which the cell lines
were maximally induced for the expression of their various TatGFP
fusion proteins. The different cell lines were incubated with 0-1000 ng/
ml of doxycycline and aliquots taken at various time points and analyzed
by flow cytometry. The cell lines expressing Tat and its deletion mutants
demonstrated very similar kinetics of GFP induction. In all the cell
lines, increasing the concentration of doxycycline produced an increase
in the percentages of GFP-expressing cells at every time point (Figure
2). The exact percentage of GFP-expressing cells at each concentration
of doxycycline tested differed slightly for each of the cell lines. However,
the maximal level of induction at 500-1000 ng/ml doxycycline was able
to induce at least 85% of the cells to express GFP in all tested cell lines.
In addition, GFP expression generally began to plateau at the 36 h time
point and was maintained for at least the 72 h period, the longest time
tested in these experiments. In four of the five cell lines (Tat101GFP,
Tat72GFP, Tat86GFP and Tat∆GFP), there were a negligible percentage
of cells exhibiting GFP fluorescence in the absence of doxycycline (0ng/
ml). The exception was the Tat48GFP cell line, where at the initial
time point approximately 6% of cells had detectable levels of GFP
fluorescence in the absence of doxycycline (0ng/ml) (Figure 2).
In an effort to compare the level of Tat expression in the engineered
cell lines to that in chronically HIV-1-infected cells, quantitative real
HIV Curr Res
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Figure 1: Expression of Tat constructs after differential induction. The left
panel shows the functional domains of the various Tat constructs and on
the right is the expression of the respective proteins from the constructs
after differential induction by doxycycline. Cells from the (A) Tat101GFP, (B)
Tat86GFP, (C) Tat72GFP, (D) Tat48GFP and (E) Tat∆GFP lines were treated
with different concentrations of doxycycline (0-1000ng/ml) for 40 h and then
the cells were lysed and protein extracted. The proteins were analyzed on
SDS-PAGE and membranes blotted with anti-Tat antibodies. GAPDH was
used as a loading control. Data are representative of two independent
experiments.

Figure 2: Time course of TatGFP expression following differential
doxycycline induction. Cells from (A) Tat101GFP, (B) Tat86GFP, (C)
Tat72GFP, (D) Tat48GFP, and (E) Tat∆GFP lines were treated with
various concentrations of doxycycline then incubated for 72 h. Aliquots
of cells were analyzed by flow cytometry (Calibur) for GFP expression
at six different time points. Data are mean of three independent
experiments.
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time PCR was performed. This was necessary as the Tat protein in
the HIV-1-infected Jurkat T cells (Jurkat-HIV-1) was undetectable
via western blots. Using primers specific for spliced Tat mRNA,
quantitative PCR detected Tat mRNA in all the cell lines as well as in the
Jurkat-HIV-1 cells. The results showed that Tat mRNA expression in
the TatGFP cell lines increased as the concentration of doxycycline was
increased from 0-1000 ng/ml. Furthermore, the amount of Tat mRNA
detected in the Jurkat-HIV-1 cells was comparable to that seen in the
TatGFP cell lines though the concentration of doxycycline needed to
reach equivalent levels of Tat mRNA differed for each cell line (Figure
3). The concentrations of Dox that gave the equivalent concentration
of Tat mRNA in HIV-1 infected cells was used in all subsequent
experiments unless indicated otherwise in order that the level of Tat
was physiologically relevant to that of an HIV-1 infected T cell.

Intracellular localization of TatGFP constructs
Studies have previously shown that fusion proteins utilizing the PTD
of the Tat protein are transported into the mitochondria from outside
the cell [26]. To determine if Tat synthesized in the cell (intracellular
Tat) enters the mitochondria, confocal microscopy was used to visualize
the intracellular localization of the different TatGFP proteins following
transfection of Cos 7 cells. These experiments were carried out in Cos
7 cells as they are more conducive to this type of image analysis than
the smaller, round Jurkat T cells that have minimal cytoplasm. The cells
were induced for Tat expression then stained for mitochondria and for
nuclear DNA. The confocal images showed that the GFP fluorescence
of the Tat101GFP and Tat72GFP proteins are co-localized with the
Hoechst stain in the nucleus (Figure 4), while the mitotracker-stained
mitochondria were evenly distributed throughout the cytoplasm
(Figure 4(A-C)). The same pattern was seen with Tat86GFP (data not
shown). In contrast, both the Tat∆GFP and Tat48GFP proteins showed
GFP fluorescence both in the nucleus and cytoplasm of the cells. This
dispersal of GFP fluorescence was also seen in the corresponding Tatexpressing Jurkat T cell lines (Supplemental Figure 1). The distribution
of the mitochondria in the cytoplasm of the Tat48GFP-expressing cell
was similar to that of the other TatGFP fusion proteins (Tat101GFP,
Tat86GFP and Tat72GFP, Figure 4D) while mitochondrial aggregation
was observed around the nucleus in cells expressing Tat∆GFP (Figure
4E). The non-punctate/diffuse nature of the GFP fluorescence in the
Tat∆GFP and Tat48GFP-expressing cells suggests there was no colocalization between GFP and the relatively structured organization
of mitochondria in these cells (Figures 4D and E). One method to
quantify protein co-localization within subcellular structures relies on
their fluorescent intensity line profiles [27]. An examination of the line
profiles for the images from the Tat∆GFP and Tat48GFP-expressing
cells showed there was no observable colocalization of GFP fluorescence
with mitotracker-stained mitochondria (Supplemental Figure 2).

Cell Viability of Tat-expressing cell lines after treatment with
SMX-HA
Earlier studies have consistently demonstrated concentrationdependent toxicity when SMX-HA is incubated with cells from patients
with a history of hypersensitivity ADRs to SMX compared to the cells
of controls [6]. Our studies have also shown that this effect on viability
is amplified in the presence of the Tat protein and is also influenced
by the amount of Tat protein in the cell [8]. The Tat-expressing cell
lines were used to determine the region or domain of the protein that
is involved in enhancing toxicity. These cell lines were evaluated using
the MTT cell viability assay and were carried out using un-induced cells
(controls) and cells exposed to different concentrations of doxycycline
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Figure 3: Quantification of Tat mRNA in the cell lines (A) Tat101, (B)
Tat101GFP and (C) data from the other cell lines. Cells were treated
with doxycycline for 40 h then RNA was extracted. Total RNA (10µg) was
reverse transcribed and used to generate a standard curve with GAPDH
serving as the housekeeping gene. Tat mRNA was detected using a Tatspecific primer. Data are mean of three independent experiments.

Figure 4: Confocal images showing localization of the Tat constructs
and mitochondrial distribution. Cells from (A) Cos, (B) Tat101GFP, (C)
Tat72GFP, (D) Tat48GFP, and (E) Tat∆GFP lines were treated with
doxycycline for 40 h, stained with Mitotracker Red and Hoechst 33258
stain, and then analyzed under a Zeiss LSM 510 META confocal
microscope. The scale bar represents 5 µm.

to induce different amounts of Tat, including that needed to reach the
Tat levels of HIV-1 infected Jurkat cells.
As previously demonstrated, neither the pro-drug SMX nor
the vehicle DMS0 (0 µM SMX-HA) had any significant effect on the
cellular viability of Jurkat T cells as the viability of each of the different
cell lines remained above 95% for the duration of the MTT assay (data
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Figure 5: The effect of Tat constructs on cell toxicity in the presence of SMX-HA. Tat expression was induced for 40 h from (A) Tat101, (B) Tat101GFP, (C)
Tat86GFP, (D) Tat72GFP, (E) Tat48GFP or (F) Tat∆GFP lines by treatment with various concentrations of doxycycline (0-1000ng/ml) then incubated with
0-400µM SMX-HA for 2 h after which the drug was replaced with media and the cells incubated at 37°C. The next day the cells were incubated with 5mg/ml
of MTT again at 37°C for a period of 4 h. The percent cell viability was then determined the following day via a plate reader at 590 nm. Data from each cell
line are mean of three independent experiments, with the exception of Jurkat E6.1. The results from the Jurkat E6.1 cells in each panel are the average of
25 different MTT experiments carried out in conjunction with different Tat-expressing cell lines over a course of several months. *P<0.001 vs. Jurkat E6.1.

not shown). While the difference in cell viability between the Tat101expressing and Jurkat E6.1 cells was significant at 400 µM SMX-HA,
there was no significant difference between the differentially induced
Tat101 cells at this concentration (Figure 5A). Cell toxicity of the Jurkat
E6.1 parental cells was significantly different from Tat101GFP cells
induced with 100 ng/ml Dox at 200 µM and 400 µM SMX-HA (Figure
5B). While cells induced with 500ng/ml doxycycline followed the
general trend of decreased cell viability with increasing concentrations
of SMX-HA, these cells did not demonstrate changes in viability that
were significantly different from doxycycline untreated cells (Figure 5B,
0 ng/ml Dox).

of cells induced with 200 ng/ml Dox and treated with 50-100 µM SMXHA in comparison to the other cell populations (Figure 5C) with a
significant increase in cell proliferation compared to Jurkat E6.1 cells
at 100µM SMX-HA. As well, there was a significant decrease between
the 200 ng/ml Dox and the 800 ng/ml Dox cell populations at 100 µM
SMX-HA (Figure 5C). There was also a significant decrease in viability
of the Tat86GFP cells compared to Jurkat E6.1 cells at 400 µM SMXHA. The Tat72GFP cell line did not show a significant decrease in cell
viability until 400 µM SMX-HA (Figure 5D). However, the differential
induction of Tat72GFP had no significant effect on cell viability at any
concentration of SMX-HA.

The Tat86GFP cell line showed a slight increase in the proliferation

In contrast, the Tat48GFP and Tat∆GFP-expressing cell lines
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demonstrated significant decreases in viability compared to Jurkat E6.1
cells at 50 µM SMX-HA, a lower treatment dose than seen with any of
the cell lines described above (Fig 5E and 5F). At 100 µM SMX-HA,
the viability of the 0 ng/ml population had dropped to approximately
40%, significantly lower than cell viabilities of 90% and above of the
cell lines expressing Tat101, Tat101GFP, Tat86GF or Tat72GFP. Cell
viability continued to decrease at the higher concentration of SMX-HA,
but there was no significant difference in the differentially induced cells.
Comparing the LC50 (lethal concentration, 50%) of each of the
cell lines demonstrated that both the Tat48GFP and Tat∆GFP cell
lines were particularly sensitive to SMX-HA. As shown in Table 1, the
LC50 values for the Jurkat E6.1, Tat101, Tat101GFP, Tat86GFP and
Tat72GFP cell lines were in the concentration range of 200-300 µM
SMX-HA while that of Tat48GFP and Tat∆GFP was 2-fold to six-fold
lower at 67-106 µM and 52-59 µM SMX-HA respectively. In an effort to
determine if this phenomenon was clone-specific, the pBIG Tat48GFP
and pBIG Tat∆GFP DNA was used to transfect Jurkat E6.1 cells and
the pool of stably selected transfectants rather than single cell clones
was used in the MTT assay. The result was an LC50 of 137-160 µM
and 138-149 µM respectively. While in both cases these LC50 values
were higher than the LC50 found in the assay using specific clones, they
were still significantly lower than the other cell lines, indicating that
the Tat48GFP and Tat∆GFP cell lines were more sensitive to SMX-HAinduced toxicity.

Generation of ROS by Tat-expressing cell lines
HIV-1 Tat has been reported to induce the formation of reactive
oxygen species (ROS) that leads to apoptosis in T cells [12]. To
determine if ROS contributed to cell death observed in the MTT assays,
the pro-oxidant effects of the Tat protein and its deletion mutants
were evaluated. Cells from the various cell lines were induced with
doxycycline and then incubated in the presence of SMX or SMX-HA
and DCFH, a cell permeable dye whose oxidized form fluoresces in the
presence of ROS. Incubation with SMX generated ROS in negligible
amounts similar to the fluorescence seen when the cells were incubated
with the vehicle DMSO. Significant production of ROS was only evident
upon the addition of SMX-HA to each of the cell lines (Figure 6)
resulting in a 3- and 8-fold increase in ROS produced. In the Tat101 and
Tat101GFP-expressing cell lines, a general trend was observed whereby
increases in the doxycycline concentration lead to small, but significant
increases in ROS production (Figures 6A and 6B). However, the
doxycycline-induced expression of Tat86GFP (Figure 6C), Tat72GFP
(Figure 6D), Tat48GFP (Figure 6E) and Tat∆GFP (Figure 6F) did not
significantly increase ROS production. In contrast, there was a marked
difference in the amount of ROS generated by the Tat101, Tat101GFP
and Tat86GFP cell lines compared to the other cell lines. Indeed the
other cell lines produced far less ROS (~40-50% less) in the presence
of SMX-HA, indicating that the pro-oxidant effect of Tat depends on
the presence of its C-terminal domain. Additionally, this property of
Tat seemed to only be effective when the protein was localized to the
nucleus, as the ROS generated by the Tat∆GFP-expressing cell line in
the presence of SMX-HA did not reach the magnitude observed in the
Tat101GFP cell line.

Expression and intracellular distribution of actin and tubulin
The discrepancy between the Tat-expressing cell lines with
significant levels of cell death after SMX-HA treatment (Figures 5E and
5F; Tat48GFP and Tat∆GFP) and those that produced considerable
amounts of ROS in the presence of SMX-HA (Fig 6A and 6B; Tat101
and Tat101GFP) suggested that oxidative stress was not the primary
HIV Curr Res
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mode of cell death. Therefore, we investigated other mechanisms
of Tat-induced cell death. Several studies have illustrated the ability
of extracellular Tat to affect the cytoskeleton, mainly by altering
cytoskeletal dynamics. Extracellular Tat can cause actin cytoskeletal
rearrangements and, at high concentrations, cytoskeletal disassembly
and collapse [23-28]. Extracellular HIV-1 Tat has also been shown to
bind tubulin, enhance microtubule polymerization and induce apoptosis
by causing the formation of abnormally stable microtubules [22,29,30].
The contribution of intracellular Tat to changes in the expression and
function of cytoskeletal proteins remains undocumented. To determine
if this is occurring in the context of SMX-HA treatment, we first induced
TatGFP expression with a low (200 ng/ml Dox) and a high (2000 ng/
ml Dox) concentration of doxycycline in Cos 7 cells stably-expressing
the different deletion mutants of Tat. We then looked at changes in the
expression of the cytoskeletal proteins β-actin and α-tubulin before
and after treatment with SMX-HA. Quantitative analysis showed
that the cell line expressing Tat101GFP had significantly lower levels
of β-actin and α-tubulin both before and after treatment with SMXHA, suggesting the full-length Tat protein was able to down-regulate
these proteins. The expression levels of β-actin and α-tubulin in cells
expressing TatΔGFP, Tat48GFP, and Tat72GFP followed in ascending
order (Figure 7).
Confocal imaging of untransfected and Tat-expressing Cos 7 cells
was also carried out to visualize the intracellular distribution of actin
and tubulin proteins after SMX-HA treatment (Figure 8). Of the stablyexpressing TatGFP cell lines examined, those expressing Tat101GFP
and Tat72GFP were able to broadly retain the organization of their
actin filaments which formed straight lines that traversed the cell.
Cells expressing Tat48GFP exhibited the most stress after SMX-HA
treatment with the cells generally exhibiting a complete disorganization
of the actin filaments that pooled at different parts of the cell, leading to
cells with a shrunken appearance. There were no straight lines of actin
filaments in the Tat∆GFP-expressing cells, but neither was there the
aggregation of actin as seen in cells expressing Tat48GFP. Consistent
with Tat stabilizing tubulin filaments, the intracellular distribution
of α-Tubulin was not affected as filaments were seen throughout the
cytoplasm of all cells. The images also did not show any discernable
interaction between the TatGFP proteins and α-tubulin. These
observations were true not only for the nuclear-localized Tat101GFP
and Tat72GFP proteins, but also the Tat48GFP and Tat∆GFP proteins
both of which exhibit a significant cytoplasmic distribution. Though
there was an increased distribution of β-actin around the edges of the
TatGFP-expressing Jurkat T cells, there was no discernable pattern or
structure to the distribution of either β-actin or α-Tubulin within the
cells, perhaps due to the limited area of the cytoplasm (Supplemental
Figure 3).

Discussion
Adverse drug reactions occur at a higher frequency in HIV-1positive patients than in the general population [1]. These reactions
occur in a number of therapeutic classes, including antiretroviral drugs
and the antibiotics used to prevent or treat opportunistic infections.
One of the most common drugs responsible for adverse effects in HIV1-infected individuals is the antimicrobial agent SMX. ADRs to SMX in
patients undergoing antiretroviral therapy arise increasingly as HIV-1
infection progresses to AIDS suggesting that HIV-1 is a key contributing
factor. Previously, our research has shown that the HIV-1 Tat protein
is such a factor as Tat expression correlates with increased sensitivity
to SMX-HA, the reactive metabolite of SMX [8,21]. In this study we
sought to determine the region of the Tat protein mediating this effect.
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Cell Line

0ng/ml Dox

400ng/ml Dox

1000ng/ml Dox

Jurkat E6.1

300

n/a

n/a

Tat101

264

250

243

Tat101GFP

302

156

265

Tat86GFP

328

310

280

Tat72GFP

262

197

228

Tat48GFP

77

67

106

Tat∆GFP

59

52

57

Pooled Tat48GFP

161

162

137

Pooled Tat∆GFP

149

146

138

Table 1: LC50 values of the various Jurkat T cell lines. All the cells used in the experiments were from clone-specific, stably-transfected cell lines with the exception of the
two cell lines given the ‘pooled’ moniker. These pooled cell lines were generated by hygromycin B selection post transfection to create a cell line of multiple clones. LC50
values were calculated using GraphPad Prism v.5 as described in the methods.

Figure 6: Reactive oxygen species generated in the presence of SMX-HA and the various Tat constructs. After induction with doxycycline, cells from
the (A) Tat101, (B) Tat101GFP, (C) Tat86GFP, (D) Tat72GFP, (E) Tat48GFP or (F) Tat∆GFP lines were seeded at a concentration of 1×106 cells/ml and
incubated with 10µM DCFH at 37oC for 1 h. There followed an incubation with different concentrations of SMX-HA for 2 h at which point the fluorescence
was determined via a plate reader. *P<0.001 vs. 0ng/ml Dox (control cells), #P<0.05 vs. 200ng/ml Dox. Data are mean of three independent experiments.
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Figure 8: Confocal images showing proteins of the cytoskeleton after
treatment with SMX-HA. Cells from (A) Cos 7, (B) Tat101GFP, (C) Tat72GFP,
(D) Tat48GFP, and (E) Tat∆GFP-expressing lines were treated with doxycycline
for 40 h, treated with 200µM SMX-HA for 2 h at 37°C then incubated in media
for another 2 h. The cells were stained with Hoechst 33258 and then fixed
with 1% PFA. α-tubulin and β-actin were visualized by immunofluorescence
staining under a Zeiss LSM 510 META confocal microscope. The scale bar
represents 20µm.

Figure 7: Expression of α-tubulin and β-actin in Tat-expressing cells. (A)
Representative western blots showing protein expression from Cos Tat101GFP
and Tat72GFP cells. Densitometric analysis of β-actin (B) and α-tubulin (C)
expression. The Cos 7 cells were induced with doxycycline for 40h and then
treated with DMSO or 200µM SMX-HA for 2hr at 37oC followed by another 2hr
incubation with media at 37oC. Protein was extracted, analyzed on SDS-PAGE
and immunoblotted with anti-α-tubulin, anti-β-actin or anti-BSA antibodies.
Exogenous BSA was used as a loading control. Data shows average of four
independent experiments. Lanes 1, 2 and 3 show protein expression from cells
induced with 0ng/ml, 200ng/ml and 2000ng/ml Dox respectively. Lanes 4, 5
and 6 show protein expression from cells induced with 0ng/ml, 200ng/ml and
2000ng/ml Dox respectively, then treated with 200µM SMX-HA. *P<0.05 vs.
Tat101GFP, +p<0.05 vs. Tat72GFP.

We also wanted to determine whether the presence of intracellular Tat
affected tubulin or actin expression levels and adversely affected their
normal intracellular organization that can result in increased cell death.
To this end, we engineered deletion mutants of Tat fused to GFP and
then established stably transfected Jurkat T and Cos7 cell lines.
Initial experiments were conducted to determine the cellular
distribution of the full-length fusion protein as well as the deletion
mutants in Cos 7 and Jurkat T cells. As expected, the full-length Tat
protein, Tat101GFP, and deletion mutants Tat86GFP and Tat72GFP
localized to the nucleus due to the presence of the previously identified
nuclear localization sequence/protein transduction domain (NLS/
PTD) [31,32]. In contrast, the Tat48GFP and Tat∆GFP fusion proteins
were distributed throughout the cell due to the deletion of the NLS/
PTD, which mediates nucleo-cytoplasmic shuttling of Tat. The
detection of GFP fluorescence in the nucleus of the Tat∆GFP and
Tat48GFP cells can be attributed to the association of the Tat proteins
HIV Curr Res
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with members of its transcriptional complex such as P-TEFb and PCAF
(p300/CREB-binding protein Associated Factor) as the key domains
for such interactions are located within the first 48 amino acids of
the N-terminus [9,33-35]. The mitochondrial aggregation seen in
Tat∆GFP-expressing cells may be an indication of an early step towards
apoptosis. Studies have shown that mitochondrial dynamics have a
significant role in regulating apoptosis. In particular, Haga et al. [36]
showed quantitatively via laser scanning cytometry that mitochondrial
aggregation precedes cytochrome c release during apoptosis and that
cytochrome c release is dependent on mitochondrial aggregation. We
have previously shown that TatGFP expression increases cytochrome c
release into the cytosol of Jurkat pBIG TatGFP cells upon treatment with
SMX-HA [21]. This suggests that Tat∆GFP expression, in particular,
primes the cell towards apoptosis more effectively than forms of Tat
largely restricted to the nucleus, a finding that is consistent with the
results of the cell viability assays.
The MTT cell viability assays previously demonstrated a significant
increase in cell toxicity in the presence of increasing concentrations of
SMX-HA [21]. The differential expression of Tat also had a cooperative
effect on SMX-HA-mediated toxicity, significantly decreasing cell
viability further as the expression of the TatGFP protein was increased
[8]. The failure of Tat72GFP expression in this paper to potentiate
SMX-HA-mediated cell death is in contrast to previously published
data [8,21]. This may be due to the fact that the sequence of the 72
amino acid Tat protein used in the aforementioned publications
(TatGFP) differs by eleven amino acids from the Tat protein used in
the current study (Tat72GFP). While both Tat variants may have the
same inherent transactivating properties it is possible that the amino
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acid differences in the Tat protein used previously impart a greater
ability to mediate T cell apoptosis. Peloponese et al. have proposed that
differences in Tat sequence may affect its ability to transactivate the
HIV-1 LTR [37]. A similar study carried out by de Mareuil et al. [29]
showed that Tat variants from patients categorized as rapid progressors
were significantly more potent in tubulin polymerization and apoptosis
induction in T cells [29]. Further experiments are needed to more
clearly define the importance of Tat amino acid sequence variation
on cell viability and whether different Tat sequence variants confer a
greater susceptibility to the development of adverse drug reactions.
The cell death seen via the MTT assays in cells expressing the fulllength Tat proteins (Tat101 and Tat101GFP) may be the result of the
generation of excess ROS, consistent with a pro-oxidant role for Tat
[12,38-40]. Experiments designed to directly compare the impact of
Tat101GFP to Tat101 on cell death, as assessed by the MTT assays,
demonstrated that the two constructs were not significantly different
from one another (data not shown). However, none of the deletion
mutants had the same effect allowing us to conclude that the full-length
Tat protein is required for the induction of increased ROS in Jurkat
cells. Though previous reports have shown that Tat deletion mutants
(Tat72 or Tat86) can induce or augment ROS production in cultured
cells, this was observed only with the addition of the recombinant
extracellular Tat protein to the cultures [12,38-40]. Despite its ability
to induce oxidative stress, expression of the full-length Tat proteins did
not cause a significant amount of cell death, even after treatment with
SMX-HA. Indeed the cell lines with lowest cell viability in response
to SMX-HA treatment (Tat48GFP and Tat∆GFP) did not produce
significant amounts of ROS. This suggests that ROS and cell death are
largely unrelated in this context.
To determine if cell death was due to the effect of Tat expression on
cytoskeletal proteins, we carried out western blot analysis, which showed
Tat101GFP was able to significantly down-regulate the expression
of cytoskeletal proteins β-actin and α-tubulin both before and after
SMX-HA treatment. This is in agreement with literature showing the
ability of Tat to down-regulate proteins including those located within
the cytoplasm [41,42]. The preferential localisation of Tat101GFP to
the nucleus and its ability to down-regulate the expression of β-actin
and α-tubulin has the effect of reducing the possibility of interaction
between the cytoskeletal proteins and Tat101GFP. This in turn ensured
that apoptosis was not triggered in these cells as shown in the MTT
viability assays. The differences seen between the Tat101GFP- and
Tat72GFP-expressing cells in the expression of β-actin and α-tubulin
further suggests that the C-terminal domain of Tat is necessary for its
role in the down-regulation of these proteins.
One possible explanation for the differences in the behaviour
of Tat protein synthesized internally (intracellular Tat) versus Tat
protein that enters the cell from the milieu (extracellular Tat) is that
intracellular Tat localizes predominantly to the nucleus where it carries
out its transactivating activities, while extracellular Tat appears to
remain largely in the cytoplasm after being endocytosed where it can
enhance the stability of polymerized microtubules and subsequently
induce apoptosis [22,30]. The ability of extracellular Tat to interact
with tubulin in the cytoplasm of the cell requires the collective integrity
of amino acids 36-39 as mutation of these four residues to alanine
was shown to inhibit this interaction [22,29]. Our Tat48GFP and
TatΔGFP deletion mutants retain amino acids 36-39 and also exhibit
the greatest reductions in cell viability. Due to the loss of the NLS/
PTD sequence the cytoplasmic concentration of these Tat48GFP and
TatΔGFP mutants rose, as they were no longer able to exit the cell
across the plasma membrane. Hence, the levels of these Tat mutants
HIV Curr Res
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in the cytoplasm would be sufficient to bind to tubulin and promote
the stabilization of polymerized microtubules in a manner similar to
that seen with extracellular Tat. This in turn leads to a lower threshold
for apoptosis and higher sensitivity to SMX-HA toxicity. Furthermore,
the divergent roles of intra- and extracellular Tat illustrates one of the
ways HIV-1 maintains survival of HIV-1-infected cells while causing
increased apoptosis of predominantly uninfected bystander cells. Taken
together these results also re-enforces the importance of Tat nuclear
sequestration, not only in promoting the transcription of the HIV1 provirus, but also in preventing premature cell death before HIV-1
replication and progeny virus production can be completed.
The effect of cytoplasmic or extracellular Tat on microtubule
dynamics and the mitochondrial aggregation that was seen in the
Tat∆GFP-expressing cells might also be related. Studies have found
a protein named C19ORF5C to be a dual function microtubule- and
mitochondria-associated protein that mediates mitotic cell death [43].
C19ORF5C is also recruited to chemically-stabilized microtubules
and accumulates on mitochondria, eventually inducing distinct
perinuclear aggregation of the mitochondria and resulting in cell
death [44,45]. The ability of extracellular Tat to bind tubulin and
stabilize microtubule polymerization leading to apoptosis has been
well established [22,29,30]. Whether or not Tat-stabilized microtubules
also recruit C19ORF5C or a similar dual function microtubule- and
mitochondria-associated protein to induce mitochondrial aggregation,
and subsequently apoptosis, requires further investigation.

Conclusion
In the general population ADRs are responsible for 3% of all
hospital admissions and occur in 10-20% of hospital inpatients
[46]. Additionally, up to 80% of HIV-1-infected patients experience
an ADR at some point during the course of their treatment thus
making ADRs a major public health issue due to their frequency and
potential for increased morbidity and mortality [2,47,48]. SMX is a
commonly used medication in both HIV-infected and uninfected
populations and its metabolism is well known, making it an ideal
model compound. The liver is quantitatively the primary site of SMX
bioactivation, though metabolism has been shown to occur in other
organs including the skin, kidney, lung and cells of the immune system
[49,50]. Furthermore, SMX metabolism by dendritic cells enhances
their state of activation [51,52]. We have previously shown that SMXHA leads to the haptenation of cellular proteins [53] including HIV1 infected Jurkat T cells and Jurkat T cells expressing the different
deletion forms of Tat (data not shown). Additionally, peripheral blood
leukocytes release cytokines on exposure to SMX-HA that are biased
to a pro-inflammatory response [54].We show here that when the
cytoplasmic content of Tat is increased, as exemplified by the Tat∆GFP
and Tat48GFP constructs in the Jurkat T cell line, this leads to a lower
threshold for cell death in the presence of SMX-HA. This leads to our
proposed model of ADRs in HIV-1 patients in which the metabolism of
SMX leads to the formation of SMX-HA in T cells and other cell types.
The death of these haptenated cells would lead to the presentation of
SMX-haptenated antigens, activation of dendritic cells and an immune
response manifesting clinically as an ADR to SMX. The exact cell death
pathway involved in the development of a primary immune response to
SMX still needs to be defined as there is past evidence of both apoptotic
and necrotic cell death [8,52]. Our data also suggests that in order to
fully understand the basis of increased ADRs in the HIV-1 population,
greater attention to HIV-1 Tat sequence variants and their impact on
disease management may be required. This would be akin to the current
situation in many jurisdictions where pharmacogenomic screening to
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identify individuals at high-risk for an ADR is recommended before
the initiation of therapy with certain antiretrovirals [55,56]. Advances
in our understanding of the mechanisms behind an ADR in HIV-1infected individuals will help the development of screening strategies
that may permit the avoidance of ADRs, the delivery of more effective
treatment and reduced hospitalizations.
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